Long-term effect of thrombolytic therapy on left ventricular ejection fraction after acute myocardial infarction.

To assess the long-term effect of thrombolytic therapy on left ventricular (LV) systolic function, 222 patients with acute myocardial infarction treated with intravenous tissue plasminogen activator within 4 hours of symptom onset underwent assessment of LV ejection fraction (EF) by radionuclide equilibrium angiography at hospital discharge and 1 year later. Mean EF at hospital discharge (46 +/- 12) was similar to that at 1 year (45 +/- 13). Stepwise multivariate linear regression analysis identified EF at discharge and patency of the infarct-related artery before discharge as independent predictors of EF change at 1 year (p = 0.

Early tPA treatment and aeromedical transport of patients with acute myocardial infarction.

Over a 2-year period 192 patients with acute myocardial infarction (AMI) were transported by helicopter and treated with recombinant tissue-plasminogen activator (tPA). All patients were entered into the Thrombolysis in Myocardial Infarction-Phase II (TIMI II) trial. Eighty-two of these patients were treated with tPA after aeromedical transport to a tertiary care center.

Tubular-toxic effects of aminoglycosides and their combinations with cephalosporins.

Cephalosporins have a distinctly different effect from that of aminoglycosides on membranes of the proximal tubule of the human kidney as measured by urinary AAP concentrations. Except for a slight influence by cephacetrile, cephalosporins showed no effect on the proximal tubule. In contrast, after three days of administration, the aminoglycosides caused a cumulative increase in membrane proteins of the proximal tubule to be excreted in the urine.

Effects of various cephalosporins on the proximal tubule of the human kidney.

Cephamandol 6.0 g, cephazolin 6.0 g or cephacetrile or cephalothin 8.